Entrada Therapeutics (TRDA) Cash from Investing Activities (2020 - 2026)

Entrada Therapeutics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at $27.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 464.23% year-over-year to $27.0 million; the TTM figure through Mar 2026 stood at $139.0 million (up 382.76% YoY), while the FY2025 annual figure was $116.8 million, up 520.2% from the prior year.
• Cash from Investing Activities was $27.0 million for Q1 2026 at Entrada Therapeutics, down from $29.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $53.4 million in Q4 2024 to a low of -$181.5 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$10.1 million across 5 years, with a median of $18.8 million in 2022.
• Biggest YoY gain for Cash from Investing Activities was 1668.98% in 2022; the steepest drop was 19892.62% in 2022.
• A 5-year view of Cash from Investing Activities shows it stood at $18.8 million in 2022, then rose by 1.34% to $19.0 million in 2023, then surged by 180.23% to $53.4 million in 2024, then sank by 45.43% to $29.1 million in 2025, then slipped by 7.32% to $27.0 million in 2026.
• The last three Cash from Investing Activities figures came in at $27.0 million (Q1 2026), $29.1 million (Q4 2025), and $49.1 million (Q3 2025), per Business Quant data.